Logo image of MRVI

MARAVAI LIFESCIENCES HLDGS-A (MRVI) Stock Fundamental Analysis

NASDAQ:MRVI - Nasdaq - US56600D1072 - Common Stock - Currency: USD

4.3  -0.28 (-6.11%)

After market: 4.58 +0.28 (+6.51%)

Fundamental Rating

2

Overall MRVI gets a fundamental rating of 2 out of 10. We evaluated MRVI against 57 industry peers in the Life Sciences Tools & Services industry. The financial health of MRVI is average, but there are quite some concerns on its profitability. MRVI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MRVI had negative earnings in the past year.
MRVI had a positive operating cash flow in the past year.
In multiple years MRVI reported negative net income over the last 5 years.
Each year in the past 5 years MRVI had a positive operating cash flow.
MRVI Yearly Net Income VS EBIT VS OCF VS FCFMRVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 200M 400M

1.2 Ratios

MRVI's Return On Assets of -17.58% is in line compared to the rest of the industry. MRVI outperforms 42.11% of its industry peers.
MRVI has a Return On Equity of -65.09%. This is in the lower half of the industry: MRVI underperforms 71.93% of its industry peers.
Industry RankSector Rank
ROA -17.58%
ROE -65.09%
ROIC N/A
ROA(3y)3.71%
ROA(5y)3.14%
ROE(3y)23.17%
ROE(5y)30.08%
ROIC(3y)N/A
ROIC(5y)N/A
MRVI Yearly ROA, ROE, ROICMRVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 20 -20 40 60 80

1.3 Margins

MRVI has a Gross Margin (46.36%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of MRVI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for MRVI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.3%
GM growth 5Y-0.98%
MRVI Yearly Profit, Operating, Gross MarginsMRVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

MRVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MRVI has been reduced compared to 1 year ago.
The number of shares outstanding for MRVI has been reduced compared to 5 years ago.
MRVI has a worse debt/assets ratio than last year.
MRVI Yearly Shares OutstandingMRVI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M
MRVI Yearly Total Debt VS Total AssetsMRVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of 1.56, we must say that MRVI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.56, MRVI perfoms like the industry average, outperforming 40.35% of the companies in the same industry.
MRVI has a Debt/Equity ratio of 1.59. This is a high value indicating a heavy dependency on external financing.
MRVI has a Debt to Equity ratio of 1.59. This is amonst the worse of the industry: MRVI underperforms 80.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.59
Debt/FCF N/A
Altman-Z 1.56
ROIC/WACCN/A
WACC11.67%
MRVI Yearly LT Debt VS Equity VS FCFMRVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M 500M

2.3 Liquidity

MRVI has a Current Ratio of 10.74. This indicates that MRVI is financially healthy and has no problem in meeting its short term obligations.
MRVI's Current ratio of 10.74 is amongst the best of the industry. MRVI outperforms 94.74% of its industry peers.
A Quick Ratio of 9.94 indicates that MRVI has no problem at all paying its short term obligations.
MRVI's Quick ratio of 9.94 is amongst the best of the industry. MRVI outperforms 94.74% of its industry peers.
Industry RankSector Rank
Current Ratio 10.74
Quick Ratio 9.94
MRVI Yearly Current Assets VS Current LiabilitesMRVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

More info and screens

3

3. Growth

3.1 Past

MRVI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -108.11%.
MRVI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -33.99%.
MRVI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.47% yearly.
EPS 1Y (TTM)-108.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-33.99%
Revenue growth 3Y0.57%
Revenue growth 5Y18.47%
Sales Q2Q%-2.49%

3.2 Future

Based on estimates for the next years, MRVI will show a very strong growth in Earnings Per Share. The EPS will grow by 21.13% on average per year.
The Revenue is expected to grow by 6.17% on average over the next years.
EPS Next Y-369.72%
EPS Next 2Y-105.46%
EPS Next 3Y-28.42%
EPS Next 5Y21.13%
Revenue Next Year-6.88%
Revenue Next 2Y-2.57%
Revenue Next 3Y1.99%
Revenue Next 5Y6.17%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MRVI Yearly Revenue VS EstimatesMRVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
MRVI Yearly EPS VS EstimatesMRVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 1 1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRVI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MRVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRVI Price Earnings VS Forward Price EarningsMRVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as MRVI.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 656.48
MRVI Per share dataMRVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

A cheap valuation may be justified as MRVI's earnings are expected to decrease with -28.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-105.46%
EPS Next 3Y-28.42%

More info and screens

0

5. Dividend

5.1 Amount

MRVI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARAVAI LIFESCIENCES HLDGS-A

NASDAQ:MRVI (2/10/2025, 8:13:25 PM)

After market: 4.58 +0.28 (+6.51%)

4.3

-0.28 (-6.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-25 2025-02-25/amc
Inst Owners91.07%
Inst Owner Change-47.01%
Ins Owners1.36%
Ins Owner Change-9.55%
Market Cap1.09B
Analysts78.18
Price Target9.52 (121.4%)
Short Float %7.46%
Short Ratio5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-127.49%
Min EPS beat(2)-154.98%
Max EPS beat(2)-100%
EPS beat(4)2
Avg EPS beat(4)-12.26%
Min EPS beat(4)-154.98%
Max EPS beat(4)182.94%
EPS beat(8)3
Avg EPS beat(8)-52.71%
EPS beat(12)7
Avg EPS beat(12)-29.98%
EPS beat(16)11
Avg EPS beat(16)-16.19%
Revenue beat(2)1
Avg Revenue beat(2)-2.46%
Min Revenue beat(2)-5.38%
Max Revenue beat(2)0.46%
Revenue beat(4)3
Avg Revenue beat(4)2.98%
Min Revenue beat(4)-5.38%
Max Revenue beat(4)12.9%
Revenue beat(8)3
Avg Revenue beat(8)-1.4%
Revenue beat(12)6
Avg Revenue beat(12)-0.2%
Revenue beat(16)9
Avg Revenue beat(16)1.26%
PT rev (1m)2.82%
PT rev (3m)-16.58%
EPS NQ rev (1m)3.45%
EPS NQ rev (3m)-786.11%
EPS NY rev (1m)3.42%
EPS NY rev (3m)-139.81%
Revenue NQ rev (1m)1.23%
Revenue NQ rev (3m)-19.58%
Revenue NY rev (1m)0.13%
Revenue NY rev (3m)-5.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.92
P/FCF N/A
P/OCF 36.28
P/B 3.15
P/tB N/A
EV/EBITDA 656.48
EPS(TTM)-0.03
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)0.12
OCFY2.76%
SpS1.1
BVpS1.37
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.58%
ROE -65.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.36%
FCFM N/A
ROA(3y)3.71%
ROA(5y)3.14%
ROE(3y)23.17%
ROE(5y)30.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.3%
GM growth 5Y-0.98%
F-Score5
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 1.59
Debt/FCF N/A
Debt/EBITDA 338.66
Cap/Depr 88.87%
Cap/Sales 15.01%
Interest Coverage N/A
Cash Conversion 1850.77%
Profit Quality N/A
Current Ratio 10.74
Quick Ratio 9.94
Altman-Z 1.56
F-Score5
WACC11.67%
ROIC/WACCN/A
Cap/Depr(3y)92.26%
Cap/Depr(5y)89.24%
Cap/Sales(3y)8.83%
Cap/Sales(5y)9.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-108.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-369.72%
EPS Next 2Y-105.46%
EPS Next 3Y-28.42%
EPS Next 5Y21.13%
Revenue 1Y (TTM)-33.99%
Revenue growth 3Y0.57%
Revenue growth 5Y18.47%
Sales Q2Q%-2.49%
Revenue Next Year-6.88%
Revenue Next 2Y-2.57%
Revenue Next 3Y1.99%
Revenue Next 5Y6.17%
EBIT growth 1Y-153.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year192.38%
EBIT Next 3Y60.62%
EBIT Next 5Y45.41%
FCF growth 1Y-102.43%
FCF growth 3Y-21.79%
FCF growth 5YN/A
OCF growth 1Y-93.96%
OCF growth 3Y-6.05%
OCF growth 5YN/A